FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents



      
           
This page is updated frequently with new G Proteins-related patent applications. Subscribe to the G Proteins RSS feed to automatically get the update: related G RSS feeds. RSS updates for this page: G Proteins RSS RSS


Date/App# patent app List of recent G Proteins-related patents
05/21/15
20150143584
 Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii patent thumbnailnew patent Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
This invention relates generally to nucleic acid sequences encoding proteins that are related to the presence of seed storage compounds in plants. More specifically, the present invention relates to arabidopsis thaliana, brassica napus, glycine max and oryza sativa nucleic acid sequences encoding sugar and lipid metabolism regulator proteins and the use of these sequences in transgenic plants.
Basf Plant Science Gmbh
05/21/15
20150140635
 Boronic and borinic acid compound as inhibitors of sulfenic acid-containing proteins patent thumbnailnew patent Boronic and borinic acid compound as inhibitors of sulfenic acid-containing proteins
A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of formula i or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein..
05/21/15
20150140580
 Antibodies to matrix metalloproteinase 9 patent thumbnailnew patent Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), such as where the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
05/21/15
20150139988
 Glycoengineered binding protein compositions patent thumbnailnew patent Glycoengineered binding protein compositions
Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..
Abbvie, Inc.
05/14/15
20150133307
 Automated screening of enzyme variants patent thumbnailAutomated screening of enzyme variants
Disclosed are methods for identifying bio-molecules with desired properties (or which are most suitable for a round of directed evolution) from complex bio-molecule libraries or sets of such libraries. Some embodiments of the present disclosure provide methods for virtually screening proteins for beneficial properties.
05/07/15
20150126452
 Protein assembler patent thumbnailProtein assembler
The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc.
Albert-luding-universitÄt Freiburg
05/07/15
20150126403
 Method of identifying proteins in human serum indicative of pathologies of human lung tissues patent thumbnailMethod of identifying proteins in human serum indicative of pathologies of human lung tissues
A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer.
Cancer Prevention And Cure, Ltd
05/07/15
20150126402
 Method for quantifying proteins and isoforms thereof patent thumbnailMethod for quantifying proteins and isoforms thereof
A method for quantifying metallothionein protein isomers is described herein. Such metallothionein isomer protein quantification is useful for detecting and monitoring disease.
University Of North Dakota
05/07/15
20150125397
 Dual specific binding proteins directed against immune cell receptors and autoantigens patent thumbnailDual specific binding proteins directed against immune cell receptors and autoantigens
Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.. .
University Of Machusetts
04/30/15
20150119558
 Cho-gmt recombinant protein expression patent thumbnailCho-gmt recombinant protein expression
The present invention provides modified cells for producing proteins with modified glycosylation patterns. Proteins produced in such cells, and the use of such proteins in medicine, and particularly in the treatment of cancer, is also provided..
Agency For Science, Technology And Research
04/30/15
20150118216

Delivery of negatively charged proteins using cationic lipids


Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro.
President And Fellows Of Harvard College
04/23/15
20150111764

Polymerized microarrays


Micropatterns of glycan-bearing brush polymers generated by the initiation of oligomerization of acrylate and methacrylate monomers from thiol-terminated surfaces. Chain lengths are controlled in situ by varying exposure time, and these multivalent glycan scaffolds detect glycan binding proteins at sub-micromolar concentrations..
New York University
04/23/15
20150111251

Tnf-alpha binding proteins


Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Abbvie Inc.
04/16/15
20150105285

Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase


The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich
04/16/15
20150104468

Site-specific labeling methods and molecules produced thereby


The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates..
Irm Llc
04/16/15
20150104452

Dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.
04/09/15
20150099290

Insertion of charge in the hydrophobic interior of proteins as a strategy for engineering ph-sensitive switches


Methods are provided for engineering non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins are also provided..
The Johns Hopkins University
04/09/15
20150098950

Liquid formulations of tumor necrosis factor-binding proteins


The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of tnf-binding protein, comprising a tnf-binding protein, a buffer and an isotonicity agent.. .
Ares Trading S.a.
04/02/15
20150094453

Isolated egg protein and egg lipid materials, and methods for producing the same


A method for separating proteins and fats from an egg mixture is disclosed herein. The method includes a step of microfiltration of the egg mixture, wherein microfiltration includes pumping across a filter an egg mixture containing egg yolk and egg whites (albumen).
Rembrandt Enterprises, Inc.
04/02/15
20150093387

Dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie, Inc.
03/26/15
20150089680

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
03/26/15
20150087819

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.
03/26/15
20150087532

Affinity reagents for protein purification


Disclosed herein are methods and compositions for purifying proteins from crude solutions.. .
The Board Of Trustees Of The Leland Stanford Junior University
03/26/15
20150086636

Myostatin inhibition for enhancing muscle and/or improving muscle function


The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin.
Nationwide Children's Hospital
03/26/15
20150086563

Alpha-4-beta-7 heterodimer specific antagonist antibody


There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.. .
Amgen Inc.
03/26/15
20150086556

Anti-activin a antibodies and uses thereof


The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.
03/26/15
20150086554

Dual variable domain immunoglobulin and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie Inc.
03/19/15
20150080558

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation
03/19/15
20150080248

Methods for isolating proteins


The invention generally relates to methods for isolating proteins. In certain aspects, methods of the invention involve preparing a plurality of sample preparations, each preparation including one or more intact cells.
Purdue Research Foundation
03/19/15
20150079062

Method for harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment


The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins.
03/19/15
20150079061

Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment


The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins.
03/19/15
20150079038

Selective recovery


Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided..
California Institute Of Technology
03/12/15
20150074852

Genetic loci associated with head smut resistance in maize


Head smut is one of the most devastating diseases in maize, causing severe yield loss worldwide. The present invention describes the fine-mapping of a major qtl conferring resistance to head smut.
E I Du Pont De Nemours And Company
03/12/15
20150074836

Mutations of the parkin gene, compositions, methods and uses


The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes..
Institut National De La Santé Et De La Recherche Médicale
03/12/15
20150072937

Chimeric peptides for the regulation of gtpases


Chimeric peptides or fusion proteins are disclosed that include a rhogap activity domain and at least one specificity domain that targets a specific rho protein. The fusion proteins can be used to inhibit any gtpase activity within a cell.
Children's Medical Center Corporation
03/12/15
20150072412

Identification of antigen or ligand-specific binding proteins


The present invention discloses novel methods for the generation, expression and screening of diverse collections of binding proteins such as antibodies or fragments thereof in vertebrate host cells in vitro, for the identification and isolation of ligand- or antigen-specific binding proteins. The methods disclosed herein allow the expression of diverse collections of binding proteins from at least one vector construct, which optionally can give rise to collections of diverse binding proteins upon transfer and expression into vertebrate host cells in situ..
4-antibody Ag
03/05/15
20150067921

Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks


A method of gene editing or gene stacking within a fad3 loci by cleaving, in a site directed manner, a location in a fad3 gene in a cell, to generate a break in the fad3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.. .
Dow Agrosciences Llc
03/05/15
20150065440

Sulfated oligosaccharide derivatives


The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.. .
Progen Pharmaceuticals Limited
03/05/15
20150065378

Synthetic oligonucleotides for detection of nucleic acid binding proteins


Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, pcr primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides..
Oregon Health & Science University
03/05/15
20150064766

Beta-glucosidase variants


The invention relates to recombinantly produced β-glucosidase variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant β-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target β-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue..
Codexis, Inc.
03/05/15
20150064744

Modified enterokinase light chain


The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site..
Novo Nordisk A/s
03/05/15
20150064688

Method of making a microfluidic device


A microfluidic device allowing for multiple discrete reactions sites and allowing for sequential reactions and sample analysis along with methods for device fabrication and use is provided. The microfluidic device provides a micro-total analysis system on a single substrate and has multiple reaction sites allowing for cascade reactions and analysis on a single chip using micro-quantities of sample and reagents.
National Science And Technology Development Agency
03/05/15
20150064211

Synthetic active peptide fragments


The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kda protein of s. Mansoni (sm14) or related fabps (fatty acid binding proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity.
FundaÇao Oswaldo Cruz - Fiocruz
03/05/15
20150064204

Gitr antigen binding proteins


Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.
03/05/15
20150064201

Antigen binding proteins to oncostatin m (osm)


The present invention concerns antigen binding proteins and fragments thereof which specifically bind oncostatin m (osm), particularly human osm (hosm) and which inhibit the binding of osm to the gp130 receptor but does not directly interact with site ii residues. The invention also concerns a method of humanising antibodies.
Glaxo Group Limited
02/26/15
20150059009

Methods for making fully human bispecific antibodies using a common light chain


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150057243

Compositions and methods for the inhibition of methyltransferases


Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, s-adenosyl-methionine-binding proteins and rna, including for the treatment of disease.. .
Northern University
02/26/15
20150056680

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses


The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc.
02/26/15
20150056634

Methods for preparing dry formulations of glucose binding protein


Methods and compositions for preparing dry formulations of glucose binding proteins (gbps) are disclosed. The gbps may be stored as a dry formulation without significant loss of activity.
Becton, Dickinson And Company
02/26/15
20150056211

Heparin-binding epidermal growth factor-like growth factor binding proteins


Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (hb-egf) and neutralize the biological functions of this growth factor.. .
Amgen, Inc.
02/26/15
20150056202

Anti-tnf/il-17 dual variable domain immunoglobulin and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie, Inc.
02/19/15
20150050715

Stably tethered structures of defined compositions with multiple functions or binding specificities


The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor.
Ibc Pharmaceuticals, Inc.
02/19/15
20150050351

Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.


This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties.
02/19/15
20150050279

B-cell receptor complex binding proteins containing t-cell epitopes


The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of cd22, cd19, cd20, and cd21, and b) an immunogenic peptide comprising at least one t-cell epitope for use in vaccination of a subject against b-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
Deutsches Krebsforschungszentrum
02/19/15
20150050238

Treatment of osteoarthritis and pain


The present invention relates to the treatment of osteoarthritis and pain using il-1α and il-1β binding proteins, including anti-il-1α and anti-il-1β antibodies and engineered multivalent and multispecific il-1α and il-1β binding proteins.. .
Abbvie Inc.
02/12/15
20150045540

Multispecific stacked variable domain binding proteins


The present invention concerns multi-specific stacked variable domain binding proteins.. .
Sea Lane Biotechnologies, Llc
02/12/15
20150045358

Pharmaceutical composition for treating disorders associated with insulin resistance


A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type a receptor, wherein the downstream signaling molecules comprise erk1/2, jnks, akt, and stat3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type a receptor or downstream signaling proteins.. .
National Central University
02/12/15
20150044705

Protein detection using modified cyclodextrins


A method is provided for detecting a protein using a cyclodextrin covalently linked to at least one label. The cyclodextrin can associate with the protein by sequestering an aromatic amino acid side-chain of the protein in its hydrophobic cavity.
Bio-rad Laboratories, Inc.
02/12/15
20150044214

Bispecific, tetravalent antigen binding proteins


The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche, Inc.
02/12/15
20150044213

Protein sustained-release injectable formulation


The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexpla).
Esbatech - A Novartis Company Llc
02/05/15
20150037339

Anti-activin a antibodies and uses thereof


The present invention provides antibodies that bind to activin a and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to activin a with high affinity.
Regeneron Pharmaceuticals, Inc.
02/05/15
20150037312

Binding proteins to the constant region of immunoglobulin g


The present invention provides polypeptides that bind to immunoglobulin g and methods for their use.. .
University Of Washington Through Its Center For Commercialization
02/05/15
20150037248

Il-1beta neutralizing human monoclonal antibodies


The present invention is directed to antigen binding proteins and in particular to il-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production..
Agency For Science, Technology And Research
01/29/15
20150031870

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.
01/29/15
20150031581

Methods and kits for determining protein-bound biomarkers


(a) automated prepurification of the sample using an effective amount of an acid protease under conditions that allow for digestion of one or more binding proteins; (b) applying said protease-digested sample onto an on-line spe column to capture at least part of said biomarker, followed by sequential washing of the solid phase; (c) eluting a fraction comprising said biomarker directly onto a liquid chromatography (lc) column comprising an apolar stationary phase and subjecting it to lc-ms or lc-ms-ms measurements to determine the amount of at least one biomarker; and (d) quantitating the biomarker(s). Also provided are kits for use in such method, for instance in the determination of vitamin d derivatives, testosterone and/or or melatonin..


Popular terms: [SEARCH]

G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         











0.2954

3319

0 - 1 - 72